James Mulay is Director at CG Oncology, Inc. (CGON). They have made 1 open-market trade across 1 company since 2025, most recently 2026-07-10.
CIK 0001684531
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CGON | 24,165 | $1.4M |
| FLGT | 10,000 | $199K |
| Total | $1.6M |
Shares reported on the most recent Form 4, priced at the 2026-07-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGON | SELL · 10b5-1 | 2026-07-10 | 2026-07-14 | $75.16 | $1.8M | -2.3% | +5.3% | -11.0% |
| CGON | SELL · 10b5-1 | 2026-06-15 | 2026-06-16 | $60.12 | $118K | +21.3% | +14.2% | +21.2% |
| CGON | SELL · 10b5-1 | 2026-04-17 | 2026-04-20 | $73.01 | $1.1M | -5.2% | -8.1% | -0.4% |
| CGON | SELL · 10b5-1 | 2026-03-16 | 2026-03-17 | $63.50 | $125K | -5.7% | -3.2% | -13.1% |
| CGON | SELL | 2026-01-09 | 2026-01-13 | $52.47 | $585K | +3.0% | -0.2% | +30.9% |
| CGON | SELL · 10b5-1 | 2025-10-09 | 2025-10-10 | $43.99 | $519K | -3.1% | -7.0% | -3.1% |
| CGON | SELL · 10b5-1 | 2025-09-29 | 2025-09-30 | $39.19 | $1000K | +8.0% | +6.1% | -0.4% |
| CGON | SELL · 10b5-1 | 2025-09-18 | 2025-09-22 | $39.01 | $1.8M | +7.9% | +13.5% | +8.6% |
| CGON | SELL · 10b5-1 | 2025-09-05 | 2025-09-08 | $31.53 | $1.7M | +15.9% | +21.5% | +27.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.